Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$5.38B
sum of reported positions
Reported positions
125
Changes vs prior quarter
121
39 new · 24 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 124 measured positions in 8 quarters, the typical new or larger position finished +0.6 pts against the S&P 500 and 52% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 15.5M | $631M | 11.7% | |
| 6.78M | $344M | 6.4% | |
| 258K | $309M | 5.7% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $4.88B | $5.38B |
| Positions | 110 | 125 |
| Biggest line | — | Edgewise Therapeutics 12% |
| 3.43M |
| $189M |
| 3.5% |
| 2.72M | $184M | 3.4% |
| 916K | $171M | 3.2% |
| 2.21M | $119M | 2.2% |
| 2.56M | $112M | 2.1% |
| 7.17M | $107M | 2.0% |
| 3.03M | $105M | 2.0% |
| 584K | $87.6M | 1.6% |
| 93K | $86.2M | 1.6% |
| 663K | $85.2M | 1.6% |
| 1.81M | $83.3M | 1.5% |
| 230K | $77M | 1.4% |
| 835K | $75.5M | 1.4% |
| 13.7M | $73.2M | 1.4% |
| 547K | $72.8M | 1.4% |
| 3.24M | $71.9M | 1.3% |
| 262K | $71.1M | 1.3% |
| 973K | $69.1M | 1.3% |
| 161K | $67M | 1.2% |
| 8.29M | $66.4M | 1.2% |
| 244K | $65.2M | 1.2% |
| 164K | $65.2M | 1.2% |
Biocryst Pharmaceuticals (BCRX)
1.43M → 1.85M shares (+30%)
Bioage Labs (BIOA)
712K → 752K shares (+6%)
Protagonist Therapeutics, Inc. (PTGX) · CALL
150K shares
Lexeo Therapeutics (LXEO)
3.6M → 3.95M shares (+10%)
Whitehawk Therapeutics (WHWK)
4.17M → 3.93M shares (−6%)
Definium Therapeutics (DFTX)
804K → 365K shares (−55%)
Spyre Therapeutics (SYRE)
186K shares
Waters Corporation (WAT)
40K shares
Monopar Therapeutics (MNPR)
157K shares
Travere Therapeutics (TVTX)
253K shares
Taysha Gene Therapies (TSHA)
2M shares
Revolution Medicines (RVMD)
52K → 71K shares (+36%)
Dianthus Therapeutics, Inc. (DNTH)
115K shares
Spruce Biosciences (SPRB)
200K shares
Lifestance Health (LFST)
500K → 947K shares (+90%)
Revolution Medicines (RVMD) · CALL
50K shares
Erasca (ERAS)
496K shares
Protara Therapeutics (TARA)
2.22M shares
Janux Therapeutics (JANX)
984K → 525K shares (−47%)
Adicet Bio (ACET)
1.03M → 845K shares (−18%)
Alto Neuroscience (ANRO)
168K → 258K shares (+54%)
Zentalis Pharmaceuticals (ZNTL)
1.39M shares
Bright Minds Biosciences (DRUG)
40K → 93K shares (+133%)
Palvella Therapeutics (PVLA) · CALL
50K → 40K shares (−20%)
Xilio Therapeutics (XLO)
592K shares
